Global Opioid Induced Constipation Market by Active Ingredients, Drug Class, Mode of Administration, Distribution Channel - Forecast 2024-2030- Product Image

Sale

Global Opioid Induced Constipation Market by Active Ingredients, Drug Class, Mode of Administration, Distribution Channel - Forecast 2024-2030

Report
185 Pages
March 2024
Region: Global
360iResearch™
ID: 5715749

UP TO €846EUR$875USD£727GBP OFF until Dec 31^st 2024

The Opioid Induced Constipation Market size was estimated at USD 65.95 million in 2023, USD 70.10 million in 2024, and is expected to grow at a CAGR of 6.69% to reach USD 103.78 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Opioid Induced Constipation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Opioid Induced Constipation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Opioid Induced Constipation Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ironwood Pharmaceuticals, Inc., Lantheus, Mylan by Viatris Inc., Pfizer, Inc., RedHill Biopharma Inc., Salix Pharmaceuticals by Bausch Health Companies Inc., Shionogo & Co. Ltd., SLA Pharma AG, Synergy Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Opioid Induced Constipation Market to forecast the revenues and analyze trends in each of the following sub-markets:

Active Ingredients
- Bulk Cathartics, Stimulant Cathartics
- Docusate Sodium
- Emollient/Lubricant Cathartics
- Lubiprostone
- Methylnaltrexone Bromide
- Naloxegol
- Osmotic laxatives
- Prostaglandins/Prokinetic Drugs
Drug Class
- Locally Acting Chloride Channel Activator (LACCA)
- Non-Selective Opioid Antagonist
- Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA)
- μ-Opioid Antagonist
Mode of Administration
- Oral
- Parenteral
Distribution Channel
- Drug Store
- Hospital Pharmacies
- Independent Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Opioid Induced Constipation Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Opioid Induced Constipation Market?
What are the technology trends and regulatory frameworks in the Opioid Induced Constipation Market?
What is the market share of the leading vendors in the Opioid Induced Constipation Market?
Which modes and strategic moves are suitable for entering the Opioid Induced Constipation Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Opioid Induced Constipation Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising geriatric population with constipation complications
5.1.1.2. Growing prevalence of kidney disorders
5.1.1.3. Surging availability of diversified treatments
5.1.2. Restraints
5.1.2.1. Stringent approval process and time-consuming
5.1.3. Opportunities
5.1.3.1. Proliferating use of opioids
5.1.3.2. Rise in availability in retail pharmacies
5.1.4. Challenges
5.1.4.1. Concern regarding opioid tolerance and addiction
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Opioid Induced Constipation Market, by Active Ingredients

6.1. Introduction
6.2. Bulk Cathartics, Stimulant Cathartics
6.3. Docusate Sodium
6.4. Emollient/Lubricant Cathartics
6.5. Lubiprostone
6.6. Methylnaltrexone Bromide
6.7. Naloxegol
6.8. Osmotic laxatives
6.9. Prostaglandins/Prokinetic Drugs

7. Opioid Induced Constipation Market, by Drug Class

7.1. Introduction
7.2. Locally Acting Chloride Channel Activator (LACCA)
7.3. Non-Selective Opioid Antagonist
7.4. Peripherally-Restricted µ-Opioid Receptor Antagonist (PAMORA)
7.5. µ-Opioid Antagonist

8. Opioid Induced Constipation Market, by Mode of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Opioid Induced Constipation Market, by Distribution Channel

9.1. Introduction
9.2. Drug Store
9.3. Hospital Pharmacies
9.4. Independent Pharmacies

10. Americas Opioid Induced Constipation Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Opioid Induced Constipation Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Opioid Induced Constipation Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
14.1.1. AstraZeneca PLC
14.1.2. Fresenius Kabi AG
14.1.3. GlaxoSmithKline PLC
14.1.4. Hikma Pharmaceuticals PLC
14.1.5. Ironwood Pharmaceuticals, Inc.
14.1.6. Lantheus
14.1.7. Mylan by Viatris Inc.
14.1.8. Pfizer, Inc.
14.1.9. RedHill Biopharma Inc.
14.1.10. Salix Pharmaceuticals by Bausch Health Companies Inc.
14.1.11. Shionogo & Co. Ltd.
14.1.12. SLA Pharma AG
14.1.13. Synergy Pharmaceuticals Inc.
14.1.14. Takeda Pharmaceutical Company Limited
14.1.15. Teva Pharmaceutical Industries Ltd.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing

List of Figures

FIGURE 1. OPIOID INDUCED CONSTIPATION MARKET RESEARCH PROCESS
FIGURE 2. OPIOID INDUCED CONSTIPATION MARKET SIZE, 2023 VS 2030
FIGURE 3. OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. OPIOID INDUCED CONSTIPATION MARKET DYNAMICS
FIGURE 7. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2030 (%)
FIGURE 8. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. OPIOID INDUCED CONSTIPATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 6. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY BULK CATHARTICS, STIMULANT CATHARTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DOCUSATE SODIUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY EMOLLIENT/LUBRICANT CATHARTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LUBIPROSTONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE BROMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PROSTAGLANDINS/PROKINETIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 15. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LOCALLY ACTING CHLORIDE CHANNEL ACTIVATOR (LACCA), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NON-SELECTIVE OPIOID ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY-RESTRICTED ?-OPIOID RECEPTOR ANTAGONIST (PAMORA), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ?-OPIOID ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. OPIOID INDUCED CONSTIPATION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 40. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 44. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 62. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 66. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 74. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 98. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 111. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 115. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 119. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 123. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 127. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 135. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 147. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 151. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 155. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 183. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 195. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023
TABLE 196. OPIOID INDUCED CONSTIPATION MARKET LICENSE & PRICING

Companies Mentioned

AstraZeneca PLC
Fresenius Kabi AG
GlaxoSmithKline PLC
Hikma Pharmaceuticals PLC
Ironwood Pharmaceuticals, Inc.
Lantheus
Mylan by Viatris Inc.
Pfizer, Inc.
RedHill Biopharma Inc.
Salix Pharmaceuticals by Bausch Health Companies Inc.
Shionogo & Co. Ltd.
SLA Pharma AG
Synergy Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	185
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 70.1 Million
Forecasted Market Value ( USD ) by 2030	$ 103.78 Million
Compound Annual Growth Rate	6.6%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3262EUR$3,374USD£2,804GBP €3624EUR$3,749USD£3,115GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4132EUR$4,274USD£3,551GBP €4591EUR$4,749USD£3,946GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5002EUR$5,174USD£4,299GBP €5558EUR$5,749USD£4,777GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5872EUR$6,074USD£5,047GBP €6524EUR$6,749USD£5,608GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7612EUR$7,874USD£6,543GBP €8458EUR$8,749USD£7,270GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Opioid-Induced Constipation - Pipeline Insight, 2024

Global Opioid Induced Constipation Market Report and Forecast 2024-2032

Opioid Induced Constipation Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application

2023 Global Forecast for Opioid Induced Constipation Drugs Market (2024-2029 Outlook) - High Tech & Emerging Markets Report

Global Opioid Use Disorder (OUD) Market Size, Share & Industry Trends Analysis Report By Drug Class (Buprenorphine, Methadone and Naltrexone), By Route of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030